Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications

In the last 30 years, since the discovery that vanadium is a cofactor found in certain enzymes of tunicates and possibly in mammals, different vanadium-based drugs have been developed targeting to treat different pathologies. So far, the in vitro studies of the insulin mimetic, antitumor and antiparasitic activity of certain compounds of vanadium have resulted in a great boom of its inorganic and bioinorganic chemistry. Chemical speciation studies of vanadium with amino acids under controlled conditions or, even in blood plasma, are essential for the understanding of the biotransformation of e.g. vanadium antidiabetic complexes at the physiological level, providing clues of their mechanism of action. The present article carries out a bibliographical research emphaticizing the chemical speciation of the vanadium with different amino acids and reviewing also some other important aspects such as its chemistry and therapeutical applications of several vanadium complexes.

Synthesis and characterization of V(IV)O complexes of picolinate and pyrazine derivatives. Behavior in the solid state and aqueous solution and biotransformation in the presence of blood plasma proteins

Oxidovanadium(IV) complexes with 5-cyanopyridine-2-carboxylic acid (HpicCN), 3,5-difluoropyridine-2-carboxylic acid (HpicFF), 3-hydroxypyridine-2-carboxylic acid (H2hypic), and pyrazine-2-carboxylic acid (Hprz) have been synthesized and characterized in the solid state and aqueous solution through elemental analysis, IR and EPR spectroscopy, potentiometric titrations, and DFT simulations. The crystal structures of the complexes (OC-6-23)-[VO(picCN)2(H2O)]·2H2O (1·2H2O), (OC-6-24)-[VO(picCN)2(H2O)]·4H2O (2·4H2O), (OC-6-24)-Na[VO(Hhypic)3]·H2O (4), and two enantiomers of (OC-6-24)-[VO(prz)2(H2O)] (Λ-5 and Δ-5) have been determined also by X-ray crystallography. 1 presents the first crystallographic evidence for the formation of a OC-6-23 isomer for bis(picolinato) V(IV)O complexes, whereas 2, 4, and 5 possess the more common OC-6-24 arrangement. The strength order of the ligands is H2hypic ≫ HpicCN > Hprz > HpicFF, and this results in a different behavior at pH 7.40. In organic and aqueous solution the three isomers OC-6-23, OC-6-24, and OC-6-42 are formed, and this is confirmed by DFT simulations. In all the systems with apo-transferrin (VO)2(apo-hTf) is the main species in solution, with the hydrolytic V(IV)O species becoming more important with lowering the strength of the ligand. In the systems with albumin, (VO)(x)HSA (x = 5, 6) coexists with VOL2(HSA) and VOL(HSA)(H2O) when L = picCN, prz, with [VO(Hhypic)(hypic)](-), [VO(hypic)2](2-), and [(VO)4(μ-hypic)4(H2O)4] when H2hypic is studied, and with the hydrolytic V(IV)O species when HpicFF is examined. Finally, the consequence of the hydrolysis on the binding of V(IV)O(2+) to the blood proteins, the possible uptake of V species by the cells, and the possible relationship with the insulin-enhancing activity are discussed.

On the transport of vanadium in blood serum

The complexation of the VO(2+) ion in several systems that can model the physiological conditions of its transport in blood serum was studied using electron paramagnetic resonance (EPR) spectroscopy. Particularly, the ternary systems formed by (i) VO(2+) and two high-molecular-mass components of blood serum, human serum apo-transferrin (hTf) and human serum albumin (HSA); (ii) VO(2+), hTf, and bL; and (iii) VO(2+), HSA, and bL, where bL is one of the six most important low-molecular-mass bioligands of the blood serum (bL = lactate, citrate, oxalate, phosphate, glycine, or histidine), were examined. The results indicate that, in aqueous solution, transferrin is a stronger binder than albumin, and at the physiological ratio, most of the VO(2+) ion is present as (VO)(2)hTf, and a small amount as (VO)(2)(d)HSA, the dinuclear species formed by albumin where the two metal ions are interacting and the spin state S is 1. Among the bL ligands, only lactate and citrate are able to bind VO(2+) in the presence of transferrin or albumin, the others not interacting at all. Finally, the quaternary systems formed by (i) VO(2+), hTf, HSA, and lactate and (ii) VO(2+), hTf, HSA, and citrate were studied. In these cases, the results suggest that the predominant species is (VO)(2)hTf, followed by the mixed complexes VO(2+)-hTf-lactate or VO(2+)-hTf-citrate, whereas (VO)(2)(d)HSA and [(VO)(2)(citrH(-1))(2)](4-) are minor components at physiological pH. The conclusions of this study give new insights on how the VO(2+) ion distributes among the blood serum components and is transported in the plasma toward the target sites in the organism.